Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients

2015 ◽  
Vol 67-69 ◽  
pp. 21-29 ◽  
Author(s):  
Gian Paolo Fadini ◽  
Mauro Rigato ◽  
Federico Boscari ◽  
Roberta Cappellari ◽  
Lisa Menegazzo ◽  
...  
2017 ◽  
Vol 125 (06) ◽  
pp. 400-407 ◽  
Author(s):  
Fang Li ◽  
Jiachao Chen ◽  
Fei Leng ◽  
Zhiqiang Lu ◽  
Yan Ling

Abstract Endothelial dysfunction is associated with the risk of cardiovascular complications in diabetic patients. Endothelial progenitor cells (EPCs) and flow-mediated dilation (FMD) are common markers of endothelial function. In this study, we aim to investigate whether the DPP-4 inhibitor saxagliptin modulate EPCs number and FMD in newly diagnosed, treatment-naive type 2 diabetic patients. This was a controlled, randomized, open-label clinical trial. Saxagliptin group and metformin group consumed either saxagliptin 5 mg per day or metformin 1 500 mg per day respectively for 12 weeks. Changes of FMD and EPCs number after 12-week intervention were the primary endpoints. 31 patients were initially enrolled and randomized to saxagliptin group (n=16) and metformin group (n=15). 27 patients completed the trial (saxagliptin group n=14 and metformin group n=13), and 4 patients dropped out during the study. FMD and EPCs number increased significantly in both saxagliptin group and metformin group, and there was no significant difference between groups. 2-h postprandial plasma glucose, HbA1c and diastolic blood pressure improved significantly in both groups, and there was no significant difference between groups. Saxagliptin and metformin had comparable beneficial effects on endothelial function.


2015 ◽  
Vol 100 (7) ◽  
pp. 2666-2672 ◽  
Author(s):  
Mauro Rigato ◽  
Cristina Bittante ◽  
Mattia Albiero ◽  
Angelo Avogaro ◽  
Gian Paolo Fadini

Context: Diabetes reduces the levels of circulating progenitor cells (CPCs) and endothelial progenitor cells (EPCs), which promote vascular repair and are inversely correlated with cardiovascular risk. Objective: The objective of the study was to test whether CPC/EPC levels predict onset/progression of microangiopathy in a cohort of type 2 diabetic (T2D) patients. Design: This was a pseudoprospective study with a 3.9-year follow-up. Setting: The study was conducted at a tertial referral diabetes outpatient clinic. Patients: A total of 187 T2D patients having a baseline determination of CPCs/EPCs participated in the study. Intervention: Baseline data on demographics, anthropometrics, concomitant risk factors, diabetic complications, and medications were collected. Main Outcome Measure: Onset or progression of microangiopathy was assessed at follow-up compared with baseline. Results: New onset or progression of microalbuminuria, chronic kidney disease, retinopathy, and neuropathy occurred in 70 patients (9.5%/y). After controlling the false discovery rate, baseline CD34+ CPCs and EPCs were significantly lower in patients with onset/progression of microalbuminuria and any microangiopathy. Patients with baseline CD34+ CPC or CD133+/kinase insert domain-containing receptor+/EPC levels below the median were more likely to experience worsening microangiopathy than those with high cell levels. Independently from confounders, including age, sex, glycated hemoglobin, and diabetes duration, CD34+ cells predicted onset/progression of microalbuminuria, retinopathy, and any microangiopathy in false discovery rate-adjusted analyses. A low CD34+ cell count limited the beneficial effects of renin-angiotensin system blockers on microalbuminuria progression. Conclusions: Levels of circulating (endothelial) progenitor cells predict microvascular outcomes in T2D. Together with previous studies showing an association with cardiovascular events, these data indicate that CPCs/EPCs represent biomarkers of the global complication burden in diabetes.


2017 ◽  
Vol 43 (2) ◽  
pp. 154-162 ◽  
Author(s):  
S. Tsukada ◽  
H. Masuda ◽  
S.Y. Jung ◽  
J. Yun ◽  
S. Kang ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Carmen Porrata-Maury ◽  
Manuel Hernández-Triana ◽  
Eduardo Rodríguez-Sotero ◽  
Raúl Vilá-Dacosta-Calheiros ◽  
Héctor Hernández-Hernández ◽  
...  

Background.In Cuba, the Ma-Pi 2 macrobiotic diet has shown positive results in 6-month assays with type 2 diabetic patients. The objective of this study was to assess the influence of this diet at short and medium terms.Methods.Sixty-five type 2 diabetic volunteers were included for dietary intervention, institutionally based for 21 days and followed later at home, until completing 3 months. 54 of them stayed until assay end. Before intervention, and after both assay periods, they were submitted to anthropometric records, body composition analyses and measurements of serum biochemical indicators, glycemic profile in capillary blood, blood pressure, and medication consumption; food intake was evaluated by the 3-day dietary recall.Results.During the intervention, the energy intake was 200 kcal higher at instance of more complex carbohydrates and dietary fiber and despite less fat and protein. Blood pressure and serum biochemical indicators decreased significantly in both periods; the safety nutritional indicators (hemoglobin, serum total proteins, and albumin) showed no variations. The global cardiovascular risk decreased and insulin consumption dropped by 46% and 64%, in both periods, respectively.Conclusions.The Ma-Pi 2 macrobiotic diet was a successful therapy at short term and after 3-month home-based intervention, for type 2 diabetics.


Sign in / Sign up

Export Citation Format

Share Document